Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays
Speaker(s): Lucy Lee
NHF's Wednesday Webinars are a free…
Efanesoctocog: A Truly Long-Acting FVIII Replacement Product
Speaker(s): Dr. Barb Konkle
NHF's Wednesday Webinars are a free education series open to providers and community members. Register to attend and learn…
FOR IMMEDIATE RELEASE
MEDIA CONTACT:
Ilana Ostrin
Senior Director of Public Relations and CommunicationsThe National Hemophilia…
On November 22, the U.S. Food and Drug Administration approved HEMGENIX (etranacogene dezaparvovec), an adeno-associated virus (AAV) vector-based gene therapy. It is approved for the treatment of adults with hemophilia B who currently use factor IX…
We invite you to join the quarterly board of directors meeting for the National Hemophilia Foundation on December 1st starting at 7:00 pm ET. This meeting will discuss NHF business operations and decisions and…
Dr. Satish Nandakumar is currently a postdoctoral fellow in the laboratory of Dr. Vijay Sankaran at the Boston Children's Hospital. Previously, he did his graduate work at the St. Jude's Children's Research Hospital in Memphis, Tennessee. In his JGP…
Per Dr. Pal, receiving the JGP Fellowship was a major milestone in her academic career and has given her the confidence to apply for future extramural funding.